Fibryga & Balfaxar
Payments companies reported to CMS as associated with Fibryga & Balfaxar. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fibryga & Balfaxar, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fibryga & Balfaxar
These are the largest totals companies reported as associated with Fibryga & Balfaxar. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Nathan Clendenen | Aurora, CO | Anesthesiology | $11,782.19 |
| Daniel Lotz | Minneapolis, MN | Anesthesiology | $7,055.69 |
| Elena Swan | Rochester, MN | Anesthesiology | $5,989.22 |
| Christoph Nabzdyk | Rochester, MN | Anesthesiology | $5,758.96 |
| Alberto Furzan Granadillo | Boston, MA | Anesthesiology | $5,755.66 |
| Georg Mackensen | Seattle, WA | Anesthesiology | $5,723.80 |
| Ravi Joshi | Dallas, TX | Anesthesiology | $5,679.58 |
| Anil Panigrahi | Stanford, CA | Anesthesiology | $5,596.83 |
| Gary Schwartz | Brooklyn, NY | Pain Medicine (Anesthesiology) | $5,385.25 |
| Nadia Hensley | Baltimore, MD | Anesthesiology | $5,368.59 |
Prescribed Fibryga & Balfaxar?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.